LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Reference Intervals Established for Serum Ferritin in Chinese Adults

By LabMedica International staff writers
Posted on 12 Nov 2019
Print article
Image: The Abbott Architect i2000SR immunoassay analyzer (Photo courtesy of Abbott Diagnostics).
Image: The Abbott Architect i2000SR immunoassay analyzer (Photo courtesy of Abbott Diagnostics).
As the foundation for the interpretation of medical laboratory data, reference intervals (RIs) for analytes are one of the most widely used clinical decision‐making tool. Nevertheless, although measurement of serum ferritin (SF) has largely replaced laboratory assays of serum iron and transferrin or total iron‐binding capacity in clinical practice, there is no gold‐standard method for measuring SF.

At present, SF can be measured using immunoassays, for example, enzyme‐linked immunosorbent assay (ELISA), electrochemiluminescent immunoassay (ECLIA), chemiluminescent immunoassay (CLIA), or immunoturbidimetric assay. Normally, a small amount of ferritin exists in the peripheral circulating blood and is called serum ferritin.

Clinical Laboratory Scientists at the Shaoxing Hospital of China Medical University (Shaoxing, China PR) obtained the SF test results of all health examinees (8,913 males aged 18‐93 years and 5,397 females aged 18‐90 years) between December 2010 and April 2019 from their laboratory information system. Venous blood samples were obtained from each study participant after a 12‐hours fasting period and collected into BD vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ, USA).

Serum was separated from the blood by centrifugation at 3,000 rpm for 5 minutes at room temperature (18‐25°C). All specimens were quantitatively determined within two hours of collection on an Abbott Architect i2000SR analyzer (Abbott Diagnostics, Chicago, IL, USA) according to the manufacturer's specifications and following the laboratory standard operating procedures. The detection kits and calibrators were provided by Abbott Diagnostics.

The scientists reported that SF levels in females were significantly different from those in males and showed a weak positive correlation with age. The RIs based on parametric approach in males were 66.12‐561.58 µg/L, whereas in all females were 3.59‐269.59 µg/L, females aged <50 years 3.26‐148.02 µg/L and those aged ≥50 years 17.28‐303.27 µg/L. The RIs based on non‐parametric approach in males were 65.00‐571.37 µg/L whereas in all females were 4.00‐254.00 µg/L, females aged <50 years 4.00‐152.00 µg/L and those aged ≥50 years 16.00‐304.05 µg/L.

The authors concluded that the present study has provided evidence that the RIs for SF in Chinese adults are markedly different from the manufacturer's recommended Rls. In Chinese adult females, the age‐specific RIs must be also taken into account. As a result, the establishment of the sex‐ and age‐specific RIs by indirect method using the data from health examination records for SF in their own laboratory would give a better chance to aid the physician in differentiating or considering treatment of iron‐deficiency anemia or a risk of iron overload than using manufacturer's recommended RIs or adopting RIs from other laboratories. The study was published on November 1, 2019 in the Journal of Clinical Laboratory Analysis.

Related Links:
Shaoxing Hospital of China Medical University
Becton Dickinson
Abbott Diagnostics


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
H.pylori Test
Humasis H.pylori Card
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.